{"entity":{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","aka":[],"tldr":"Cheap, essential chemotherapy drugs such as cisplatin keep running short because there is little profit in making them. A publicly-backed non-profit manufacturer would guarantee supply at a fair price.","summary":"Extend the Civica Rx and California CalRx model to a portfolio of essential oncology generics that repeatedly fall into shortage (cisplatin, carboplatin, methotrexate, fluorouracil, vincristine, etoposide, BCG): a non-profit manufacturer or contracted network with public capital, long-term purchase agreements from hospital systems and national payers, redundant production sites, and transparent cost-plus pricing. Where the public option also supplies low- and middle-income countries through pooled procurement, it addresses global access at the same time. The problem is not scientific; it is a market that rewards exit from low-margin sterile injectables.","asOf":"2026-09-08","links":[{"label":"Civica Rx","url":"https://civicarx.org/"},{"label":"CalRx","url":"https://calrx.ca.gov/"}],"tags":[],"related":["idea-fund-global-cancer-fund","idea-fund-public-car-t-manufacturing"],"cancers":[],"sections":[],"technologies":["platinum","cytotoxic-chemotherapy"],"targets":[],"drugs":["carboplatin","paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-global-access","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A public-option supplier covering the ten most shortage-prone oncology generics eliminates treatment delays attributable to those shortages in participating health systems within three years and holds prices within 20% of the pre-shortage median.","rationale":"Civica has supplied dozens of shortage-prone hospital generics since 2018 with stable prices; the 2023 cisplatin and carboplatin shortage in the US forced rationing of curative treatment, an outcome that would be unthinkable for a high-margin product. Public options for essential goods are a standard response to thin-market failure.","test":"Fund one non-profit line for cisplatin and carboplatin with purchase commitments from a consortium of cancer centres, and track fill rates, delays and prices against the national market over two years.","maturity":"early-clinical","actor":"policy","cost":"large","horizonYears":3},"route":"/ideas/idea-fund-public-option-generic-oncology/","neighbours":{"idea":[{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/"},{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}